These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1040 related articles for article (PubMed ID: 25944523)

  • 21. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
    Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
    Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
    Händel MN; Cardoso I; von Bülow C; Rohde JF; Ussing A; Nielsen SM; Christensen R; Body JJ; Brandi ML; Diez-Perez A; Hadji P; Javaid MK; Lems WF; Nogues X; Roux C; Minisola S; Kurth A; Thomas T; Prieto-Alhambra D; Ferrari SL; Langdahl B; Abrahamsen B
    BMJ; 2023 May; 381():e068033. PubMed ID: 37130601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
    Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
    Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
    Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
    Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
    Cranney A; Wells G; Willan A; Griffith L; Zytaruk N; Robinson V; Black D; Adachi J; Shea B; Tugwell P; Guyatt G;
    Endocr Rev; 2002 Aug; 23(4):508-16. PubMed ID: 12202465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
    Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
    Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
    Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
    JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
    Langdahl B
    Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies.
    Alves C; Mendes D; Penedones A; Oliveira T; Donato A; Batel-Marques F
    Int J Clin Pharm; 2024 Apr; 46(2):357-367. PubMed ID: 38112890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
    Martens MG
    J Reprod Med; 2003 Jun; 48(6):425-34. PubMed ID: 12856513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Kendler DL; Marin F; Zerbini CAF; Russo LA; Greenspan SL; Zikan V; Bagur A; Malouf-Sierra J; Lakatos P; Fahrleitner-Pammer A; Lespessailles E; Minisola S; Body JJ; Geusens P; Möricke R; López-Romero P
    Lancet; 2018 Jan; 391(10117):230-240. PubMed ID: 29129436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: review of the literature.
    Iwamoto J; Sato Y; Takeda T; Matsumoto H
    Drugs Aging; 2012 Mar; 29(3):191-203. PubMed ID: 22372723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.
    Ellis AG; Reginster JY; Luo X; Bushmakin AG; Williams R; Sutradhar S; Mirkin S; Jansen JP
    Curr Med Res Opin; 2014 Aug; 30(8):1617-26. PubMed ID: 24773456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of teriparatide compared with risedronate on FRAX
    Body JJ; Marin F; Kendler DL; Zerbini CAF; López-Romero P; Möricke R; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Minisola S; Geusens P
    Osteoporos Int; 2020 Oct; 31(10):1935-1942. PubMed ID: 32474650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
    Li P; Wu X; Li Y; Huang J
    Clin Invest Med; 2022 Sep; 45(3):E14-22. PubMed ID: 36149052
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.